Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Clinical trial NCT04095273 · COMPLETED
Trial details
- NCT number
- NCT04095273
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-30
- Primary completion
- 2022-11-24
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.